TABLE 5.
Effects of different compounds on VPB incubation period.
| Group | Dose (mg/kg) | Number (with arrhythmia/total number) | VPB incubation period (s) |
|---|---|---|---|
| Control | — | 10/10 | 116.5 ± 36.4 |
| Lidocaine | 5.0 | 12/21 | 280.3 ± 128.7* |
| Propafenone | 3.2 | 10/10 | 193.3 ± 39.9* |
| Compound 1 | 0.05 | 10/10 | 199.4 ± 79.7 |
| 0.20 | 11/12 | 202 ± 56.4* | |
| 0.40 | 10/13 | 493.7 ± 148.7*+# | |
| 0.60 | 11/25 | 547.3 ± 241.8*# | |
| Compound 2 | 0.05 | 11/11 | 168.4 ± 74.0 |
| 0.20 | 11/13 | 441.4 ± 202.3*# | |
| 0.30 | 10/22 | 800.5 ± 353.2*+# | |
| 0.40 | 10/28 | 920.5 ± 358.1*+# | |
| Compound 4 | 0.05 | 10/10 | 201.0 ± 84.9 |
| 0.20 | 11/13 | 377.8 ± 184.0* | |
| 0.40 | 19/25 | 382.9 ± 146.5*# |
Data are presented as mean ± S.D. *p < 0.05 compared with control group, +p < 0.05 compared with the lidocaine group, #p < 0.05 compared with the propafenone group.